Cystic Fibrosis Clinical Trial
— MUCO TRANSPLANOfficial title:
Non-respiratory Comorbidities Observed in Pulmonary French Transplant Patients With Cystic Fibrosis - Exploratory Study From the French Cohort on 2004-2014.
Verified date | November 2017 |
Source | Hospices Civils de Lyon |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Pulmonary transplantation is the reference treatment for chronic terminal respiratory failure
in patients with cystic fibrosis. These are mainly bi-pulmonary transplants (cardiopulmonary
transplants are exceptional). The annual number of pulmonary transplants in France for cystic
fibrosis is about 90. In 2013, the transplant involves a total of more than 600 patients with
cystic fibrosis. The average age at the time of the transplant is 28.5 years (2013 data,
French cystic fibrosis register), compared to 58 years for patients transplanted to all
pathologies. Cystic fibrosis accounts for 25% of adult bi-pulmonary grafts. Pediatric
transplants are currently very rare.
The median survival after pulmonary transplantation in cystic fibrosis is currently 8.5 years
(and 10 years when considering patients surviving 3 months, ie excluding early mortality).
Cystic fibrosis is the pathology associated with better survival after pulmonary
transplantation given the young age of patients (28.5 years on average).
The non-respiratory comorbidities associated with transplantation, all underlying pathologies
combined, and referenced in the Registry of the International Society for Heart and Lung
Transplantation (ISHLT) are: hypertension, diabetes, renal insufficiency, Dyslipidemia,
cancers. Their frequency increases with the survival time of transplanted patients. Cystic
fibrosis is associated with non-respiratory comorbidities, the frequency of which increases
with age - diabetes, osteoporosis, renal insufficiency, hepatopathy, neoplastic pathologies -
and may become worse after transplantation.
The main objective is to estimate the incidence of non-respiratory co-morbidities after lung
transplantation in the cohort of patients with cystic fibrosis grafted in the Rhône-Alpes
region.
Status | Completed |
Enrollment | 120 |
Est. completion date | October 30, 2017 |
Est. primary completion date | June 1, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - Patients with clinical diagnosis of cystic fibrosis - Patients with Pulmonary transplant between 01/01/2004 and 31/12/2014 - Patients followed-up in one of the two pulmonary transplantation centers in the Rhône-Alpes region (Lyon, Grenoble) Exclusion Criteria: - Patients followed in Rhône Alpes but transplanted elsewhere in France will not be included. - Patient refusing to participate in the study |
Country | Name | City | State |
---|---|---|---|
France | Service de médecine interne Centre Hospitalier Lyon Sud, Hospices Civils de Lyon | Pierre-Bénite |
Lead Sponsor | Collaborator |
---|---|
Hospices Civils de Lyon |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of co-morbidities after lung transplantation | The incidence rate will be calculated at 1 year follow-up after lung transplantation. The comorbidities studied will be: diabetes kidney failure high blood pressure hepatopathies undernutrition osteoporosis neoplasms, and in particular colon cancer gynecological complications (viral and neoplastic) |
1 year | |
Primary | Incidence of co-morbidities after lung transplantation | The incidence rate will be calculated at 2 years follow-up after lung transplantation. The comorbidities studied will be: diabetes kidney failure high blood pressure hepatopathies undernutrition osteoporosis neoplasms, and in particular colon cancer gynecological complications (viral and neoplastic) |
2 years | |
Primary | Incidence of co-morbidities after lung transplantation | The incidence rate will be calculated at 5 years follow-up after lung transplantation. The comorbidities studied will be: diabetes kidney failure high blood pressure hepatopathies undernutrition osteoporosis neoplasms, and in particular colon cancer gynecological complications (viral and neoplastic) |
5 years | |
Primary | Incidence of co-morbidities after lung transplantation | The incidence rate will be calculated at 10 years follow-up after lung transplantation. The comorbidities studied will be: diabetes kidney failure high blood pressure hepatopathies undernutrition osteoporosis neoplasms, and in particular colon cancer gynecological complications (viral and neoplastic) |
10 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04696198 -
Thoracic Mobility in Cystic Fibrosis Care
|
N/A | |
Completed |
NCT00803205 -
Study of Ataluren (PTC124™) in Cystic Fibrosis
|
Phase 3 | |
Terminated |
NCT04921332 -
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
|
N/A | |
Completed |
NCT03601637 -
Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del
|
Phase 3 | |
Terminated |
NCT02769637 -
Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)
|
||
Recruiting |
NCT06030206 -
Lung Transplant READY CF 2: A Multi-site RCT
|
N/A | |
Recruiting |
NCT06012084 -
The Development and Evaluation of iCF-PWR for Healthy Siblings of Individuals With Cystic Fibrosis
|
N/A | |
Recruiting |
NCT06032273 -
Lung Transplant READY CF 2: CARING CF Ancillary RCT
|
N/A | |
Recruiting |
NCT06088485 -
The Effect of Bone Mineral Density in Patients With Adult Cystic Fibrosis
|
||
Recruiting |
NCT05392855 -
Symptom Based Performance of Airway Clearance After Starting Highly Effective Modulators for Cystic Fibrosis (SPACE-CF)
|
N/A | |
Recruiting |
NCT04056702 -
Impact of Triple Combination CFTR Therapy on Sinus Disease.
|
||
Recruiting |
NCT04039087 -
Sildenafil Exercise: Role of PDE5 Inhibition
|
Phase 2/Phase 3 | |
Completed |
NCT04038710 -
Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.
|
||
Completed |
NCT04058548 -
Clinical Utility of the 1-minute Sit to Stand Test as a Measure of Submaximal Exercise Tolerance in Patients With Cystic Fibrosis During Acute Pulmonary Exacerbation
|
N/A | |
Completed |
NCT03637504 -
Feasibility of a Mobile Medication Plan Application in CF Patient Care
|
N/A | |
Recruiting |
NCT03506061 -
Trikafta in Cystic Fibrosis Patients
|
Phase 2 | |
Completed |
NCT03566550 -
Gut Imaging for Function & Transit in Cystic Fibrosis Study 1
|
||
Recruiting |
NCT04828382 -
Prospective Study of Pregnancy in Women With Cystic Fibrosis
|
||
Completed |
NCT04568980 -
Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
|
||
Recruiting |
NCT04010253 -
Impact of Bronchial Drainage Technique by the Medical Device Simeox® on Respiratory Function and Symptoms in Adult Patients With Cystic Fibrosis
|
N/A |